TOWA Pharmaceutical Co (FRA:6QC) ROCE %: -10.52% (As of Mar. 2026)


FRA:6QC TOWA Pharmaceutical Co Ltd FRA:6QC
88 GF Score
Price €19.60
GF Value €17.54
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is TOWA Pharmaceutical Co ROCE %?

TOWA Pharmaceutical Co FRA:6QC -3.92% 88 ROCE % is -10.52% as of Mar. 2026. GuruFocus rates FRA:6QC with a GF Score™ of 88/100 and a GF Value™ of €17.54 (Fairly Valued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TOWA Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2026 was -10.52%.

TOWA Pharmaceutical Co  (FRA:6QC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TOWA Pharmaceutical Co ROCE % Related Terms

TOWA Pharmaceutical Co ROCE % Historical Data

* Premium members only.

The historical data trend for TOWA Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TOWA Pharmaceutical Co ROCE % Chart

TOWA Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.89 1.97 7.43 7.66 3.79

TOWA Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.20 4.61 8.70 12.45 -10.52
FRA:6QC
88GF Score
TOWA Pharmaceutical Co Ltd FRA:6QC
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TOWA Pharmaceutical Co ROCE % Calculation

TOWA Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=84.089/( ( (2921.765 - 545.719) + (2590.867 - 528.035) )/ 2 )
=84.089/( (2376.046+2062.832)/ 2 )
=84.089/2219.439
=3.79 %

TOWA Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-222.516/( ( (2677.797 - 511.173) + (2590.867 - 528.035) )/ 2 )
=-222.516/( ( 2166.624 + 2062.832 )/ 2 )
=-222.516/2114.728
=-10.52 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -10.52% mean?
TOWA Pharmaceutical Co (FRA:6QC) has a ROCE % of -10.52% as of Mar. 2026.
Is TOWA Pharmaceutical Co's ROCE % too high?
TOWA Pharmaceutical Co's current ROCE % is -10.52%. Overall, TOWA Pharmaceutical Co has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TOWA Pharmaceutical Co's ROCE % compare to ZTS?
TOWA Pharmaceutical Co's ROCE % of -10.52% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TOWA Pharmaceutical Co's current ROCE % is -10.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TOWA Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co (FRA:6QC) is currently considered Fairly Valued. The stock's GF Value™ is €17.54, compared to a current price of €19.60 — trading 11.7% above its estimated fair value. The current ROCE % is -10.52%. TOWA Pharmaceutical Co's overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For TOWA Pharmaceutical Co (FRA:6QC), the current ROCE % is -10.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TOWA Pharmaceutical Co (FRA:6QC) Overvalued in 2026?

Based on GuruFocus' analysis, TOWA Pharmaceutical Co stock appears to be overvalued. The current stock price of €19.60 is trading 11.7% above its estimated GF Value™ of €17.54. GuruFocus considers TOWA Pharmaceutical Co to be Fairly Valued.

Key valuation signals for FRA:6QC:

  • ROCE %: -10.52%
  • GF Value™: €17.54 vs. price of €19.60 (11.7% above fair value)
  • GF Score™: 88/100 with 5 warning signs

No single metric tells the full story. See the FRA:6QC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TOWA Pharmaceutical Co Business Description

Other Exchanges 4553:Japan
Address 2-11, Shinbashi-cho, Kadoma, Osaka, JPN, 571-8580
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
88GF Score

Get the complete analysis for FRA:6QC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.60
Price
€17.54
GF Value